Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2006

View Archived Issues

Gabapentin effects differ in studies of alcohol withdrawal and cocaine dependence

Seikagaku terminates option and license agreements

Shire files SPD-476 in Europe for ulcerative colitis

Second pivotal phase III trial begins for Xerecept

Arrow advances lead hepatitis C compound into full preclinical development

Phase I study of EVT-101 completes single ascending dose component

ISIS-301012 begins phase II for familial hypercholesterolemia

CSA-54 shows potent virucidal activity in in vitro tests against HIV

Phase II study to investigate CA4P with chemoradiotherapy in NSCLC

Calando and NCI collaborate to develop RNAi therapeutics

Canadian clearance for phase Ib/II trial of CTCE-9908 in advanced cancers

Research collaboration to evaluate nasal delivery for Alzheimer's disease

Bicifadine studied in new phase II trial for diabetic peripheral neuropathy

Resistentia gets Swedish clearance for phase I study of RP-01

Antiangiogenic effects of TSRATS-4

Small interfering RNAs prevent herpes simplex virus-2 infection in vivo

New antiangiogenic and antitumor DNA vaccine targets angiostatin receptor

Peramivir a possible alternative to oseltamivir in treating influenza

EXEL-2880: preclinical antitumor and antiangiogenic activity

Eisai looks back on productive quarter

CHMP recommends approval of Exelon for Parkinson's disease dementia

Telbivudine submitted for European approval

Maribavir receives fast track designation for prevention of CMV infection

Recent patents impart novel therapeutic agents for respiratory disorders

Recent patents describe novel agents for cardiovascular disorders

Gardasil BLA granted priority review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...